Skip to main content

Intelligent Bio Solutions Inc. (Nasdaq: INBS) Announces Major Steps Towards FDA Clearance and U.S. Launch.

Intelligent Bio Solutions Inc. (Nasdaq: INBS) Announces Major Steps Towards FDA Clearance and U.S. Launch.

In July 2024, Intelligent Bio Solutions Inc. (Nasdaq: INBS) revealed that three UK-based manufacturers adopted its Fingerprint Drug Screening System, renowned for its fast, intelligent, and non-invasive drug detection through fingertip sweat. This innovation’s biocompatibility has propelled it towards FDA clearance, with plans for a U.S. launch in 2025.

On August 1, Intelligent Bio Solutions entered a strategic partnership with CenExel, a nationwide clinical research site network operator. This collaboration is part of an FDA clinical study plan, involving a method comparison clinical study.

Under the study, 135 healthy adult subjects across three sites will participate in tests comparing the fingerprint sweat opiate screening results with those from the traceable LC-MS/MS method, the current gold standard.

This partnership and study are the final stages of Intelligent Bio Solutions' clinical study plan. Over the past two months, the company has made significant progress and is on track to submit its 510(k) application to the FDA in Q4 2024. The company praised the efforts of its clinical study partners and team for their role in the smooth progression of this process.

Intelligent Bio Solutions Inc. is moving closer to revolutionizing drug screening with its innovative, non-invasive solutions.

Here are four healthcare companies under $10 demonstrating robust market trends, volume, and awareness:

  1. Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) – Focuses on therapies for central nervous system disorders.
  2. Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) – Specializes in cancer immunotherapy products.
  3. Savara Inc. (NASDAQ: SVRA) – Develops therapies for rare respiratory diseases.
  4. Eyenovia, Inc. (NASDAQ: EYEN) – Innovates in ophthalmic treatments.
  5. Telescope Innovations Corp. CSE: TELI | OTCQB: TELIF develops scalable manufacturing processes for the pharmaceutical and chemical industries, using robotic platforms and AI.

 

These companies are actively involved in the healthcare sector, showcasing market strength through their innovative products and services. 

 

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com


Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.